Impact of multi-agent systemic therapy on all-cause and disease-specific survival for people living with HIV who are diagnosed with non-Hodgkin lymphoma: population-based analyses from the state of Georgia
Authors:
- 28 October 2022
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 64 (1) , 151-160
Abstract
For people living with HIV (PLWH) who are subsequently diagnosed with non-Hodgkin lymphoma (NHL), we investigate the impact of standard-of-care (SoC) cancer treatment on all-cause, NHL-specific, and HIV-specific survival outcomes. The focus is on a registry-derived, population-based sample of HIV + adults diagnosed with NHL within 2004–2012 in the state of Georgia. SoC treatment is defined as receipt of multi-agent systemic therapy (MAST). In multivariable survival analyses, SoC cancer treatment is significantly associated with better all-cause and NHL-specific survival, but not better HIV-specific survival across 2004–2017. Having a CD4 count <200 near the time of cancer diagnosis and Ann Arbor stage III/IV disease are associated with worse all-cause and HIV-specific survival; the effects on NHL survival trend negative but are not significant. Future work should expand the geographic base and cancers examined, deepen the level of clinical detail brought to bear, and incorporate the perspectives and recommendations of patients and providers.Keywords
Funding Information
- NIH (P30AI050409)
- Winship Cancer Institute of Emory University (HHSN261201800003I, HHSN26100001)
- National Cancer Institute (5NU58DP003875-04)
- Centers for Disease Control and Prevention
- Biostatistics and Bioinformatics Shared Resource of the Winship Cancer Institute
- National Cancer Institute (P30CA138292)
This publication has 25 references indexed in Scilit:
- Disparities in the treatment and outcomes of lung cancer among HIV-infected individualsAIDS, 2013
- Clinical Presentation, Treatment, and Outcomes Among 65 Patients with HIV-Associated Lymphoma Treated at the University of North Carolina, 2000–2010AIDS Research and Human Retroviruses, 2012
- Immortal Time Bias: A Frequently Unrecognized Threat to Validity in the Evaluation of Postoperative RadiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Introduction: Understanding and Influencing Multilevel Factors Across the Cancer Care ContinuumJournal of the National Cancer Institute Monographs, 2012
- The Use and Interpretation of Competing Risks Regression ModelsClinical Cancer Research, 2012
- Landmark Analysis at the 25-Year Landmark PointCirculation: Cardiovascular Quality and Outcomes, 2011
- Immortal Person-Time in Studies of Cancer OutcomesJournal of Clinical Oncology, 2009
- Competing Risk Regression Models for Epidemiologic DataAmerican Journal of Epidemiology, 2009
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- Opportunistic Infection and Immunologic Function in Patients With Human Immunodeficiency Virus-Associated Non-Hodgkin's Lymphoma Treated With ChemotherapyJNCI: Journal of the National Cancer Institute, 1997